These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35477308)

  • 1. Biocomposite-based nanostructured delivery systems for the treatment and control of inflammatory lung diseases.
    Mukherjee D; Bhatt S
    Nanomedicine (Lond); 2022 May; 17(12):845-863. PubMed ID: 35477308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle Delivery Systems with Cell-Specific Targeting for Pulmonary Diseases.
    Deng Z; Kalin GT; Shi D; Kalinichenko VV
    Am J Respir Cell Mol Biol; 2021 Mar; 64(3):292-307. PubMed ID: 33095997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical nanoparticles for next generation drug delivery to the lungs.
    van Rijt SH; Bein T; Meiners S
    Eur Respir J; 2014 Sep; 44(3):765-74. PubMed ID: 24791828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesoporous silica nanoparticles for pulmonary drug delivery.
    García-Fernández A; Sancenón F; Martínez-Máñez R
    Adv Drug Deliv Rev; 2021 Oct; 177():113953. PubMed ID: 34474094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology-based therapeutics for targeting inflammatory lung diseases.
    Loo CY; Lee WH
    Nanomedicine (Lond); 2022 May; 17(12):865-879. PubMed ID: 35315290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotechnological Systems and Lung: A Perfect Combination for Lung Pharmaceutical Applications.
    Santonocito D; Puglia C
    Curr Med Chem; 2023; 30(6):725-743. PubMed ID: 36043745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases.
    Pramanik S; Mohanto S; Manne R; Rajendran RR; Deepak A; Edapully SJ; Patil T; Katari O
    Mol Pharm; 2021 Oct; 18(10):3671-3718. PubMed ID: 34491754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy.
    He Y; Liang Y; Han R; Lu WL; Mak JCW; Zheng Y
    J Control Release; 2019 Nov; 314():48-61. PubMed ID: 31644935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.
    Lim YH; Tiemann KM; Hunstad DA; Elsabahy M; Wooley KL
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Nov; 8(6):842-871. PubMed ID: 27016134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patented therapeutic drug delivery strategies for targeting pulmonary diseases.
    Thakur AK; Chellappan DK; Dua K; Mehta M; Satija S; Singh I
    Expert Opin Ther Pat; 2020 May; 30(5):375-387. PubMed ID: 32178542
    [No Abstract]   [Full Text] [Related]  

  • 11. In-vitro and in-vivo characterization of a multi-stage enzyme-responsive nanoparticle-in-microgel pulmonary drug delivery system.
    Mejías JC; Roy K
    J Control Release; 2019 Dec; 316():393-403. PubMed ID: 31715279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.
    Zhang M; Lu H; Xie L; Liu X; Cun D; Yang M
    Adv Drug Deliv Rev; 2023 Dec; 203():115144. PubMed ID: 37995899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems.
    Dua K; Bebawy M; Awasthi R; Tekade RK; Tekade M; Gupta G; De Jesus Andreoli Pinto T; Hansbro PM
    Pharm Nanotechnol; 2017; 5(4):243-249. PubMed ID: 28786352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of nanoparticles for the treatment of lung diseases.
    Azarmi S; Roa WH; Löbenberg R
    Adv Drug Deliv Rev; 2008 May; 60(8):863-75. PubMed ID: 18308418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary delivery of anti-inflammatory agents.
    Ali ME; McConville JT; Lamprecht A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):929-45. PubMed ID: 25534260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy.
    Jin Z; Gao Q; Wu K; Ouyang J; Guo W; Liang XJ
    Adv Drug Deliv Rev; 2023 Nov; 202():115111. PubMed ID: 37820982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Molecular Therapeutics for Pulmonary Diseases: Addressing the Need for Precise Drug Delivery.
    Carneiro S; Müller JT; Merkel OM
    Handb Exp Pharmacol; 2024; 284():313-328. PubMed ID: 38177399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Drug Targeting using siRNA-based Nano Therapeutics for Pulmonary Diseases.
    Krishnaswami V; Kandasamy R
    Curr Pharm Des; 2022; 28(28):2279-2282. PubMed ID: 35894459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micro- and nanocarrier-mediated lung targeting.
    Kurmi BD; Kayat J; Gajbhiye V; Tekade RK; Jain NK
    Expert Opin Drug Deliv; 2010 Jul; 7(7):781-94. PubMed ID: 20560777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary drug delivery: a role for polymeric nanoparticles?
    d'Angelo I; Conte C; Miro A; Quaglia F; Ungaro F
    Curr Top Med Chem; 2015; 15(4):386-400. PubMed ID: 25579350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.